Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

13.54 +0.05 (+0.41%)
Streaming Delayed Price Updated: 10:17 AM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 Next >
Why Roivant Sciences Stock Bounced Back on Tuesday
Investors were in a forgiving mood after Monday's dispiriting earnings release. 
Via The Motley Fool
Why Roivant Sciences Stock Was Slipping on Monday
The distinctive biotech wasn't a sector favorite as the trading week began. 
Via The Motley Fool
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings.... 
Via MarketMinute
Topics Economy Stocks
A Glimpse of Roivant Sciences's Earnings Potential
 
Via Benzinga
What Does the Market Think About Roivant Sciences?
 
Via Benzinga
Peering Into Roivant Sciences's Recent Short Interest
 
Via Benzinga
Earnings Scheduled For August 11, 2025
 
Via Benzinga
Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday?
Wall Street hovered slightly higher by midday Thursday, giving up a chunk of strong overnight gains in futures markets that were triggered by a federal court ruling suspending a large portion of... 
Via Benzinga
Topics Government
Earnings Scheduled For May 29, 2025
 
Via Benzinga
Roivant Sciences's Earnings Outlook
 
Via Benzinga
Roivant Sciences Q3 Earnings Assessment
 
Via Benzinga
The Analyst Landscape: 5 Takes On Roivant Sciences
 
Via Benzinga
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift
The company is getting a new chief executive and a new chief financial officer amid sweeping changes. 
Via Investor's Business Daily
Topics Government
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402. 
Via Benzinga
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
The companies reported positive results for their lead asset in patients with two rare diseases. 
Via Investor's Business Daily
Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday?
Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while... 
Via Benzinga
Topics Government World Trade
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Price Over Earnings Overview: Roivant Sciences
 
Via Benzinga
4 Analysts Assess Roivant Sciences: What You Need To Know
 
Via Benzinga
Roivant Sciences Tops Q3 Expectations
Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline. 
Via The Motley Fool
Earnings Scheduled For February 10, 2025
 
Via Benzinga
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
 
Via Benzinga
Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching
President Trump's cabinet is comprised of millionaires, billionaires and leaders in business who founded or led public companies. Here's the TRUMP index stocks. 
Via MarketBeat
Topics Government
'I'm One Of You' – How 'Anti-Woke' Warrior Vivek Ramaswamy Became A Billionaire At Only 38
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ as his final trade. 
Via Benzinga
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2... 
Via Benzinga
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 million and up to $280 million in future milestone payments. 
Via Benzinga
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the... 
Via Benzinga
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.